Boston Scientific invests in Corautus again
This article was originally published in Clinica
Boston Scientific will increase its equity investment in Corautus Genetics, the Atlanta, Georgia-based company with which it is collaborating on gene therapy technology development to treat severe coronary artery disease.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.